Cogent Biosciences (NASDAQ:COGT) Downgraded by Zacks Investment Research to Sell

0
34

Cogent Biosciences stock has undergone multiple analysts rating changes in the recent past.  Cogent Biosciences Downgraded by Zacks Investment Research on 10/18/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Cogent Biosciences traded down -$0.34 on Monday, reaching $8.90. 201912 shares of the stock traded hands, compared to its average volume of 134816. Shares of Cogent Biosciences were trading at $8.90 on Monday. The firm’s 50 day moving average is $8.37 and its 200 day moving average is $8.56.Cogent Biosciences has a 12 month low of $8.57 and a 12 month high of $13.90. While on yearly highs and lows, Cogent Biosciences’s today has traded high as $9.28 and has touched $8.57 on the downward trend. See More Analyst Rating at: RATING

Cogent Biosciences Earnings and What to expect: 

Cogent Biosciences last issued its earnings results on August 15th, 2021. The technology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.07. Cogent Biosciences has generated ($16.08) earnings per share over the last year (($11.90) diluted earnings per share). Earnings for Cogent Biosciences are expected to decrease in the coming year, from ($1.62) to ($1.66) per share. Cogent Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

Earnings for Cogent Biosciences are expected to decrease in the coming year, from ($1.62) to ($1.66) per share. The P/E ratio of Cogent Biosciences is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cogent Biosciences is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cogent Biosciences has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Cogent Biosciences (NASDAQ:COGT) Moving Average Technical Analysis

5 day Moving Average is $8.82 And 5 day price change is $0.74 (9.07%)  with average volume for 5 day average is 222,680. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $8.55 and 20 day price change is $0.10 (1.14%) and average 20 day moving volume is 145,185. 50 day moving average is $8.37  and 50 day price change is $1.63 ( 22.42%)  and with average volume for 50 days is : 171,078. 200 day moving average is $8.56  and 200 day price change is -$2.33 (-20.75%)  and with average volume for 200 days is : 300,327.

Other owners latest trading in Cogent Biosciences :

  • On 8/23/2021 shares held by Morgan Stanley were 7,690 which equates to market value of $62K and appx 0.00% owners of Cogent Biosciences
  • On 8/17/2021 shares held by Invesco Ltd. were 729,846 which equates to market value of $5.92M and appx 0.00% owners of Cogent Biosciences
  • On 8/17/2021 shares held by Bridgeway Capital Management LLC were 39,690 which equates to market value of $0.32M and appx 0.00% owners of Cogent Biosciences
  • In total Institutional ownership equates to Institutional Ownership Percentage: 91.03% for Cogent Biosciences

See More Analyst Rating at: RATING